NU6300 Inhibits Gasdermin D Cleavage and Palmitoylation: Mechanistic Insights into Pyroptosis Suppression

Study Background and Research Question

Gasdermin D (GSDMD) is a central effector protein in the execution of pyroptosis, an inflammatory form of programmed cell death implicated in a range of diseases, including sepsis, inflammatory bowel disease, and cancer. Upon activation by inflammatory caspases, GSDMD is cleaved to release an active N-terminal fragment (GSDMD-N) that oligomerizes and forms pores in the plasma membrane, leading to membrane rupture and pro-inflammatory cytokine release. Palmitoylation at cysteine-191 of GSDMD is also essential for its membrane localization and pore-forming activity (paper). While several small molecules—including Disulfiram—have been shown to covalently modify this cysteine residue to block pyroptosis (internal_article), the precise molecular consequences and selectivity of such inhibition remain incompletely understood. Jiang et al. address the question: can small molecule inhibitors be designed to specifically and covalently target GSDMD at C191, and what are the downstream effects on inflammasome signaling and pyroptotic cell death?

Key Innovation from the Reference Study

This study identifies NU6300 as a selective, covalent GSDMD inhibitor that reacts specifically with cysteine-191. Unlike previously described agents, NU6300 not only blocks GSDMD cleavage but also impairs palmitoylation at C191. This dual action prevents both the activation and the membrane localization of GSDMD-N, thereby suppressing pore formation and subsequent pyroptosis. Notably, NU6300 does not inhibit upstream inflammasome events such as ASC oligomerization or caspase-1 activation in AIM2- and NLRC4-mediated pathways, but exerts a broader inhibitory effect on NLRP3 inflammasome signaling (paper), revealing pathway-specific feedback mechanisms.

Methods and Experimental Design Insights

Jiang et al. employed a systematic screening approach to identify NU6300's activity against pyroptotic cell death, using lactate dehydrogenase (LDH) release as a readout in human monocytes and murine macrophages. Biochemical assays demonstrated that NU6300 forms a covalent adduct at GSDMD C191, confirmed by mass spectrometry and site-directed mutagenesis. The impact on GSDMD cleavage and palmitoylation was assessed with immunoblotting and acyl-biotin exchange assays. In vitro, NU6300 selectively blocked GSDMD processing and palmitoylation, but did not inhibit upstream inflammasome activation in all pathways. In vivo efficacy was evaluated in mouse models of dextran sulfate sodium (DSS)-induced colitis and lipopolysaccharide (LPS)-induced sepsis, monitoring clinical scores, cytokine levels, and survival rates (paper).

Protocol Parameters

• pyroptosis cell death assay | LDH release quantification | human monocytes, mouse macrophages | quantifies membrane rupture as a readout for pyroptotic cell death | paper
• GSDMD inhibition assay | covalent labeling at C191 (mass spectrometry, mutagenesis) | recombinant protein, cell lysates | confirms target engagement and specificity | paper
• palmitoylation assay | acyl-biotin exchange, immunoblotting | full-length and N-terminal GSDMD | detects impairment of lipid modification critical for membrane localization | paper
• cytokine release | multiplex cytokine bead array | cell culture supernatants, mouse serum | assesses downstream inflammatory output | paper
• in vivo efficacy | DSS-induced colitis; LPS-induced sepsis | C57BL/6 mice | evaluates therapeutic potential and disease modulation | paper
• workflow suggestion | Disulfiram as a GSDMD inhibitor (5–20 μM, 24 h, cell-based assays) | human/rodent cell lines, including breast cancer MDA-MB-231 | supports comparative studies with established dopamine β-hydroxylase inhibitors | workflow_recommendation

Core Findings and Why They Matter

NU6300 was found to covalently bind C191 of GSDMD, efficiently blocking both its cleavage and palmitoylation. This mechanism prevents GSDMD-N from localizing to the plasma membrane and forming pores, thereby suppressing pyroptosis in both human and mouse immune cells. Importantly, NU6300's effects are pathway-selective: it does not interfere with upstream inflammasome activation in AIM2 and NLRC4 settings, but inhibits NLRP3-driven responses, indicating a feedback regulation unique to the NLRP3–GSDMD axis (paper). In mouse models, NU6300 treatment led to significant protection against both DSS-induced colitis and LPS-induced sepsis, supporting the translational relevance of targeting GSDMD palmitoylation and cleavage in inflammatory disease contexts.

Comparison with Existing Internal Articles

Several internal resources contextualize GSDMD inhibition strategies and the use of small molecules such as Disulfiram:

• Disulfiram: Proteasome and Dopamine β-Hydroxylase Inhibitor describes Disulfiram’s dual function—not only as a dopamine β-hydroxylase inhibitor but also as a potent copper-complexed proteasome inhibitor, relevant for apoptotic cancer cell death induction and breast cancer MDA-MB-231 cell line research. This article details validated protocols for Disulfiram’s use in both cancer and inflammasome workflows, highlighting its established role in blocking GSDMD-mediated pyroptosis.
• Disulfiram: Proteasome Inhibitor and Pyroptosis Modulator further elaborates on Disulfiram’s capacity to modulate inflammasome signaling, with actionable troubleshooting and workflow guidance for research applications.
• The current study (Jiang et al.) expands on these findings by introducing NU6300, which, unlike Disulfiram, selectively blocks both cleavage and palmitoylation of GSDMD at C191. This specificity provides a tool for dissecting pathway-dependent mechanisms in pyroptosis and may inform future design of GSDMD-targeted therapeutics (internal_article).

Limitations and Transferability

While NU6300 demonstrates high selectivity and efficacy in vitro and in vivo, several limitations should be considered:

• The molecular specificity for GSDMD C191 was established, but potential off-target effects in complex biological systems require further profiling (paper).
• Although both Disulfiram and NU6300 covalently modify GSDMD, differences in pathway selectivity, cellular uptake, and long-term toxicity remain to be systematically compared (internal_article).
• The translation of these findings to chronic disease models or human clinical settings is as yet unproven, highlighting the need for additional pharmacokinetic and safety studies.

Why this cross-domain matters, maturity, and limitations

The connection between GSDMD inhibition and disease modulation extends beyond inflammation into cancer research, as GSDMD-driven pyroptosis can influence tumor microenvironments. Disulfiram, for instance, is widely used in apoptotic cancer cell death induction and proteasomal chymotrypsin-like activity inhibition, especially in breast cancer MDA-MB-231 models (internal_article). However, the direct applicability of NU6300 in oncology has not been tested; such cross-domain translation should be approached with caution until supported by further evidence (paper).

Research Support Resources

Researchers seeking to investigate GSDMD inhibition or conduct parallel studies on pyroptosis and proteasome biology can leverage established compounds such as Disulfiram (SKU A4015). Disulfiram is a clinically validated dopamine β-hydroxylase inhibitor with extensive documentation as a copper-complex proteasome inhibitor, suitable for workflows involving apoptotic cancer cell death induction, proteasomal chymotrypsin-like activity inhibition, and inflammasome pathway research (source: workflow_recommendation). For detailed protocols and troubleshooting, consult APExBIO’s technical dossier or refer to the associated internal literature.